Kategorie: Indolente Lymphome/MCL
EudraCT-Nr.: 2020-002935-30
Rekrutierung beginnt in Kürze
Venetoclax in combination with the BTK inhibitor Ibrutinib and rituximab or conventional chemotherapy (bendamustine) and ibrutinib and rituximab in patients with treatment naïve Mantle Cell Lymphoma not eligible for high dose therapy - The European Mantle Cell Lymphoma Elderly III-Trial
Medizinische Klinik und Poliklinik III
Marchioninistr. 15| 81377 München